Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of EC-2629

Trial Profile

A phase I trial of EC-2629

Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs EC 2629 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 08 Aug 2017 According to an Endocyte media release, the company has filed an Investigational New Drug (IND) application for EC2629.
    • 20 Mar 2017 New trial record
    • 10 Mar 2017 According to an Endocyte media release, this trial is expected to initiate enrollment in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top